

PARTICIPATING FACULTY

Emerging Antithrombotic Therapies: New Developments in Acute Care Medicine

This supplement to *The American Journal of Managed Care* provides information on the medical and economic burden associated with acute coronary syndromes (ACS) and emergent treatment of ACS. Efficacy, safety, and cost-effectiveness of current and emerging antithrombotic therapies are discussed.

Faculty

Charles L. Campbell, MD

Director of Coronary Care Unit
Assistant Professor of Medicine
Division of Cardiovascular
Medicine
University of Kentucky
Lexington, Kentucky

Edith A. Nutescu, PharmD

Clinical Associate Professor
Department of Pharmacy
Practice
University of Illinois at Chicago—
College of Pharmacy
Chicago, Illinois

Alexander G. G. Turpie, MD

Professor of Medicine
McMaster University
Internist
Hamilton Health Sciences
General Hospital
Hamilton, Ontario, Canada

Disclosure Statement

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

■ **Edith A. Nutescu, PharmD**

Speakers' bureau:
GlaxoSmithKline
Sanofi-Aventis

■ **Alexander G. G. Turpie, MD**

Consultant:
Bayer
GlaxoSmithKline
Pfizer Inc
Sanofi-Aventis
Speakers' bureau:
Pfizer Inc
Sanofi-Aventis

The following participant has declared no financial affiliations with corporate organizations:

■ **Charles L. Campbell, MD**

Thomas May and Kenneth Lane contributed to the writing of the articles in this supplement, as noted in the footnotes.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

Emerging Antithrombotic Therapies: New Developments in Acute Care Medicine

GOAL

To provide participants with information about medical and economic costs of treatment of acute coronary syndromes (ACS), and to present data from recent clinical trials on emerging antithrombotic therapies.

TARGET AUDIENCE

This activity is intended for physicians, medical directors, pharmacists, and pharmacy directors.

EDUCATIONAL OBJECTIVES

After completing this continuing education activity, the participant should be able to:

- Describe the medical and economic cost burden of ACS and related thrombotic illnesses.
- Discuss the older and emerging acute care therapies for ACS.
- Compare the safety and cost-effectiveness of the newer ACS pharmacotherapies, the pentasaccharide factor Xa inhibitors.
- Understand the formulary issues involved in ACS treatment.

CONTINUING MEDICAL EDUCATION ACCREDITATION

The University of Cincinnati College of Medicine designates this activity for a maximum of 2 *AMA PRA Category 1 CME credit(s)*[™]. Each physician should claim only those hours that he/she actually spends in the educational activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians. Release Date: December 1, 2006. Expiration Date: December 1, 2007.

CONTINUING PHARMACY EDUCATION ACCREDITATION



Pharmacy Times/Ascend Media is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-06-011-H01. Release Date: December 1, 2006. Expiration Date: December 1, 2007.

FUNDING

This program is supported by an unrestricted educational grant from **GlaxoSmithKline**.

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Fondaparinux sodium is currently under review by the FDA for use in acute coronary syndromes (ACS); however, it is not yet approved for that indication.